Transient metals enhance cytotoxicity of curcumin: Potential involvement of the NF-κB and mTOR signaling pathways

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3249-3255

  Lou, Jessica R ^a   Zhang, Xiao Xi ^a   Zheng, Jie ^a   Ding, Wei Qun ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

A2780; Cancer; Copper; Curcumin; mTOR; NF B

Indexed keywords

ALPHA TOCOPHEROL; COPPER; COPPER CHLORIDE; CURCUMIN; FERROUS CHLORIDE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METAL; REACTIVE OXYGEN METABOLITE; ZINC CHLORIDE; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADJUVANT THERAPY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CYTOTOXICITY; HUMAN; HUMAN CELL; METAL BINDING; PRIORITY JOURNAL; WESTERN BLOTTING; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; COPPER; CURCUMIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROSCOPY, CONFOCAL; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77958575111     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Huang R, Wallqvist A and Covell DG: Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem Pharmacol 69: 1009-1039, 2005. (Pubitemid 40349015)
2. Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ and Merajver SD: Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-1672, 2003. (Pubitemid 36554589)
3. Richardson DR: Therapeutic potential of iron chelators in cancer therapy. Adv Exp Med Biol 509: 231-249, 2002.
4. Ding WQ and Lind SE: Metal ionophores - An emerging class of anticancer drugs. IUBMB Life 67: 1013-1018, 2009.
5. Brewer GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 226: 665-673, 2001.
6. Lovejoy DB and Richardson DR: Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 10: 1035-1049, 2003.
7. Hatcher H, Planalp R, Cho J, Torti FM and Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65: 1631-1652, 2008.
8. Sreejayan Rao MN: Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46: 1013-1016, 1994.
9. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA and Sartor RB: Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483, 1999.
10. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270: 24995-25000, 1995.
11. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ and Huang S: Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 69: 1000-1008, 2009.
12. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo MA, Gonzalez-Vergara E and Rojas-Hernandez A: Spectrophotometric and electrochemical determination of the formation constants of the complexes curcumin-Fe(III)-water and curcumin-Fe(II)-water. Spectrochim Acta A Mol Biomol Spectrosc 60: 1105-1113, 2004.
13. Baum L and Ng A: Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis 6: 367-377; discussion 443-449, 2004.
14. Ding WQ, Liu B, Vaught JL, Palmiter RD and Lind SE: Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther 5: 1864-1872, 2006.
15. Ding WQ, Liu B, Vaught JL, Yamauchi H and Lind SE: Anticancer activity of the antibiotic clioquinol. Cancer Res 65: 3389-3395, 2005.
16. Oikawa S, Yamada K, Yamashita N, Tada-Oikawa S and Kawanishi S: N-acetylcysteine, a cancer chemopreventive agent, causes oxidative damage to cellular and isolated DNA. Carcinogenesis 20: 1485-1490, 1999. (Pubitemid 29385434)
17. Ding WQ, Vaught JL, Yamauchi H and Lind SE: Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther 3: 1109-1117, 2004.
18. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007.
19. Barik A, Mishra B, Shen L, Mohan H, Kadam RM, Dutta S, Zhang HY and Priyadarsini KI: Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic Biol Med 39: 811-822, 2005.
20. Dancey J: mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219, 2010.
21. Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934-2949, 2004. (Pubitemid 38638854)
22. Zhai S, Yang L, Cui QC, Sun Y, Dou QP and Yan B: Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem 15: 259-269, 2010.
23. Chen D, Milacic V, Frezza M and Dou QP: Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des 15: 777-791, 2009.